TARA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases...

Stats
今日成交量	134 286
平均成交量	282 874
市值	33.27M
EPS	$0 ( 2024-05-02 )
下一个收益日期	( $-0.810 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.820
ATR14	$0.0180 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-19	Shefferman Jesse	Buy	59 000	Common Stock
2024-01-19	Shefferman Jesse	Sell	7 803	Common Stock
2024-01-19	Shefferman Jesse	Buy	357 000	Stock Option (Right to Buy)
2024-01-19	Bandari Jathin	Buy	137 000	Stock Option (Right to Buy)
2024-01-19	Bandari Jathin	Buy	23 000	Common Stock

INSIDER POWER
91.93
Last 95 transactions
Buy: 2 372 974 \| Sell: 114 915

音量相关性

長: 0.13 (neutral)

短: -0.84 (strong negative)

Signal:(43.165) Neutral

Protara Therapeutics Inc 相关性

10 最正相关
PXLW	0.933
SRTS	0.925
KTCC	0.915
IMNM	0.908
LXRX	0.907
FWRG	0.905
KYMR	0.903
SWTX	0.897
COHR	0.892
NWSA	0.892

10 最负相关
RTPY	-0.921
RMRM	-0.872
KVSB	-0.863
DSWL	-0.86
SGML	-0.857
VALN	-0.857
SRNGW	-0.856
BFRI	-0.856
BSGM	-0.854
BIOL	-0.853

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Protara Therapeutics Inc 相关性 - 货币/商品

-0.21
( neutral )

-0.48
( neutral )

0.00
( neutral )

-0.41
( neutral )

0.35
( neutral )

0.47
( neutral )

Protara Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-341 000 (0.00 %)
EPS:	$-3.57

FY	2023
营收:	$0
毛利润:	$-341 000 (0.00 %)
EPS:	$-3.57

FY	2022
营收:	$0
毛利润:	$-247 000 (0.00 %)
EPS:	$-5.76

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-6.53

Financial Reports:

No articles found.

Protara Therapeutics Inc

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.